Revision history of "Optimisation of immunotherapy procedures in cancer (OPTICANCER)" (Q3696006)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

10 October 2024

  • curprev 11:3911:39, 10 October 2024DG Regio talk contribs 67,871 bytes +2 Changed label, description and/or aliases in pt
  • curprev 11:3911:39, 10 October 2024DG Regio talk contribs 67,869 bytes +2 Set a claim value: summary (P836): A mudança mais recente e provavelmente mais importante no campo da oncologia nos últimos anos tem sido o desenvolvimento da imunooncologia, especialmente os inibidores do ponto de controlo imunológico. O uso dos anticorpos monoclonais que visam PD-1 e PD-L1 alterou significativamente a aproximação à terapia do cancro. De facto, estas drogas são eficazes em uma vasta gama de cancros, têm poucos efeitos secundários e conduzem às respostas duradouras n...

22 March 2024

12 January 2024

19 June 2023

12 June 2023

8 June 2023

18 July 2022

  • curprev 12:5912:59, 18 July 2022DG Regio talk contribs 64,614 bytes +44,874 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, it, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et,

14 January 2022

13 January 2022

6 December 2021

1 December 2021

  • curprev 10:2010:20, 1 December 2021DG Regio talk contribs 12,732 bytes +2,174 Created claim: summary (P836): Die jüngste und wahrscheinlich wichtigste Veränderung im Bereich der Onkologie in den letzten Jahren ist die Entwicklung der Immunonkologie, insbesondere von Immunkontrollpunkt-Inhibitoren. Die Verwendung monoklonaler Antikörper gegen PD-1 und PD-L1 hat das Verständnis der Krebstherapie erheblich verändert. In der Tat sind diese Medikamente bei einer Vielzahl von Krebserkrankungen wirksam, haben wenig Nebenwirkungen und führen zu dauerhaften Rea...

27 November 2021

  • curprev 13:0213:02, 27 November 2021DG Regio talk contribs 10,558 bytes −2,362 Removed claim: summary (P836): Le changement le plus récent et probablement le plus important dans le domaine de l‚oncologie ces dernières années est le développement de l‘immuno-oncologie, et plus particulièrement des inhibiteurs de point de contrôle immunitaire. L‚utilization des anticorps monoclonaux ciblant PD-1 et PD-L1 a considérablement modifié la façon d‘appréhender la thérapie anticancéreuse. De effet, ces médicaments sont efficaces sur un large éventail de cancers...
  • curprev 01:0501:05, 27 November 2021DG Regio talk contribs 12,920 bytes +2,362 Created claim: summary (P836): Le changement le plus récent et probablement le plus important dans le domaine de l‚oncologie ces dernières années est le développement de l‘immuno-oncologie, et plus particulièrement des inhibiteurs de point de contrôle immunitaire. L‚utilization des anticorps monoclonaux ciblant PD-1 et PD-L1 a considérablement modifié la façon d‘appréhender la thérapie anticancéreuse. De effet, ces médicaments sont efficaces sur un large éventail de cancers,...

26 November 2021

24 November 2021

22 November 2021

  • curprev 10:3610:36, 22 November 2021DG Regio talk contribs 10,007 bytes +122 Changed label, description and/or aliases in en: translated_label
  • curprev 10:3610:36, 22 November 2021DG Regio talk contribs 9,885 bytes +2,033 Created claim: summary (P836): The most recent and probably most important change in the field of oncology in recent years has been the development of immunooncology, especially immune control point inhibitors. The use of monoclonal antibodies targeting PD-1 and PD-L1 has significantly altered the approach to cancer therapy. Indeed, these drugs are effective on a wide range of cancers, have few side effects and lead to lasting responses in metastatic patients. However, in mos...

17 November 2021